Health
CanSino to start Phase III trial of COVID-19 vaccine in Saudi – The Jakarta Post – Jakarta Post
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
Last month, CanSino’s co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV.
The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body…
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News19 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
General23 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation